Digital Health Technologies (DHTs) differ in application and design. There are technologies that control autonomous functions (e.g. controlling insulin delivery in insulin pumps), wearables that detect a fall or cardiac arrhythmia and report it to emergency contacts, apps that monitor or moderate mental health (e.g. anxiety attacks), or patient-centric digital portals for navigating the patient journey, with associated optimization of coordination efforts.
The adoption of DHTs continues to surge in Europe, and the growing market’s estimated value is roughly $267 billion by 2030. DHTs represent innovation, potential cost savings and align with public health priorities.
However, market access, reimbursement and patient access considerations vary considerably from country to county across the continent, and those variations are compounded by unique regional and local policies. Anyone commercializing DHTs in Europe will need an intimate understanding of country-specific requirements and reimbursement pathways to successfully bring a product to market.
In this white paper, Certara’s Global Market Access experts provide insight into basic DHT procedures in select countries including Germany, France, the UK, Spain, Italy, Poland and Hungary. Critical aspects of reimbursement, pricing and patient access for these countries are also discussed.
Authors
Kurt Neeser, PhD, MPH, Senior Director Value & Access
kurt.neeser@certara.com
Michael Heupel, MBA, Senior Director EU Market Access
michael.heupel@certara.com
Malwina Holownia, PhD, Associate Director HEOR & MA CEE
malwina.holownia@certara.com